Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved rucaparib (Rubraca), a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login